|
1
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Søreide K, Sandvik OM, Søreide JA, Giljaca
V, Jureckova A and Bulusu VR: Global epidemiology of
gastrointestinal stromal tumours (GIST): A systematic review of
population-based cohort studies. Cancer Epidemiol. 40:39–46. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors. Gastroenterol Clin North Am. 42:399–415. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nilsson B, Bümming P, Meis-Kindblom JM,
Odén A, Dortok A, Gustavsson B, Sablinska K and Kindblom LG:
Gastrointestinal stromal tumors: the incidence, prevalence,
clinical course, and prognostication in the preimatinib mesylate
era-a population-based study in western Sweden. Cancer.
103:821–829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Joensuu H: Gastrointestinal stromal tumor
(GIST). Ann Oncol. 17 (Suppl 10):x280–x286. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Pathology and prognosis at different sites. Semin
Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blanke CD, Demetri GD, von Mehren M,
Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD,
Roberts PJ, Heinz D, et al: Long-term results from a randomized
phase II trial of standard- versus higher-dose imatinib mesylate
for patients with unresectable or metastatic gastrointestinal
stromal tumors expressing KIT. J Clin Oncol. 26:620–625. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blay JY, Kang YK, Nishida T and von Mehren
M: Gastrointestinal stromal tumours. Nat Rev Dis Primers. 7:222021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antonescu CR, Besmer P, Guo T, Arkun K,
Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer
S, et al: Acquired resistance to imatinib in gastrointestinal
stromal tumor occurs through secondary gene mutation. Clin Cancer
Res. 11:4182–4190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al-Share B, Alloghbi A, Al Hallak MN,
Uddin H, Azmi A, Mohammad RM, Kim SH, Shields AF and Philip PA:
Gastrointestinal stromal tumor: A review of current and emerging
therapies. Cancer Metastasis Rev. 40:625–641. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurokawa Y, Honma Y, Sawaki A, Naito Y,
Iwagami S, Komatsu Y, Takahashi T, Nishida T and Doi T: Pimitespib
in patients with advanced gastrointestinal stromal tumor
(CHAPTER-GIST-301): A randomized, double-blind, placebo-controlled
phase III trial. Ann Oncol. 33:959–967. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Q, Li C, Yang H, Zhao H, Zhao J, Bi
X, Li Z, Huang Z, Zhang Y, Zhou J and Cai J: Radiofrequency
ablation versus resection for resectable liver metastases of
gastrointestinal stromal tumours: Results from three national
centres in China. Clin Res Hepatol Gastroenterol. 43:317–323. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoon IS, Shin JH, Han K, Kim PN, Kim KH,
Kang YK and Ko HK: Ultrasound-guided intraoperative radiofrequency
ablation and surgical resection for liver metastasis from malignant
gastrointestinal stromal tumors. Korean J Radiol. 19:542018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xue A, Gao X, He Y, Shu P, Huang X, Sun J,
Lu J, Hou Y, Fang Y and Shen K: Role of surgery in the management
of liver metastases from gastrointestinal stromal tumors. Front
Oncol. 12:9034872022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamanaka T, Takaki H, Nakatsuka A, Uraki
J, Fujimori M, Hasegawa T, Sakuma H and Yamakado K: Radiofrequency
ablation for liver metastasis from gastrointestinal stromal tumor.
J Vasc Interv Radiol. 24:341–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
DeMatteo RP, Lewis JJ, Leung D, Mudan SS,
Woodruff JM and Brennan MF: Two hundred gastrointestinal stromal
tumors: Recurrence patterns and prognostic factors for survival.
Ann Surg. 231:51–58. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mazzocca A, Napolitano A, Silletta M,
Spalato Ceruso M, Santini D, Tonini G and Vincenzi B: New frontiers
in the medical management of gastrointestinal stromal tumours. Ther
Adv Med Oncol. 11:17588359198419462019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jung JH, Won HJ, Shin YM and Kim PN:
Safety and efficacy of radiofrequency ablation for hepatic
metastases from gastrointestinal stromal tumor. J Vasc Interv
Radiol. 26:1797–1802. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones RL, McCall J, Adam A, O'Donnell D,
Ashley S, Al-Muderis O, Thway K, Fisher C and Judson IR:
Radiofrequency ablation is a feasible therapeutic option in the
multi modality management of sarcoma. Eur J Surg Oncol. 36:477–482.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Keung EZ, Raut CP and Rutkowski P: The
landmark series: Systemic therapy for resectable gastrointestinal
stromal tumors. Ann Surg Oncol. 27:3659–3671. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
DeMatteo RP, Shah A, Fong Y, Jarnagin WR,
Blumgart LH and Brennan MF: Results of hepatic resection for
sarcoma metastatic to liver. Ann Surg. 234:540–548. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Turley RS, Peng PD, Reddy SK, Barbas AS,
Geller DA, Marsh JW, Tsung A, Pawlik TM and Clary BM: Hepatic
resection for metastatic gastrointestinal stromal tumors in the
tyrosine kinase inhibitor era. Cancer. 118:3571–3578. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Q, Li C, Yang H, Zhao H, Wu J, Zhao
J, Bi X, Li Z, Huang Z, Zhang Y, et al: Resection combined with TKI
therapy for resectable liver metastases of gastrointestinal stromal
tumours: Results from three national centres in China. J
Gastrointest Surg. 24:1330–1341. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seesing MF, Tielen R, van Hillegersberg R,
van Coevorden F, de Jong KP, Nagtegaal ID, Verhoef C and de Wilt
JH; Dutch Liver Surgery Working Group, : Resection of liver
metastases in patients with gastrointestinal stromal tumors in the
imatinib era: A nationwide retrospective study. Eur J Surg Oncol.
42:1407–1413. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
DeMatteo RP, Maki RG, Singer S, Gonen M,
Brennan MF and Antonescu CR: Results of tyrosine kinase inhibitor
therapy followed by surgical resection for metastatic
gastrointestinal stromal tumor. Ann Surg. 245:347–352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haller F, Detken S, Schulten HJ, Happel N,
Gunawan B, Kuhlgatz J and Füzesi L: Surgical management after
neoadjuvant imatinib therapy in gastrointestinal stromal tumours
(GISTs) with respect to imatinib resistance caused by secondary KIT
mutations. Ann Surg Oncol. 14:526–532. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vassos N, Agaimy A, Hohenberger W and
Croner RS: Management of liver metastases of gastrointestinal
stromal tumors (GIST). Ann Hepatol. 14:531–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
